Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page




    Clinical evaluation of BD Veritor™ SARS-CoV-2 and Flu HGNC A+B Assay for point-of-care (POC) System

    Authors:

    doi:10.1101/2021.05.04.21256323 Date: 2021-05-04 Source: medRxiv

    Differential diagnosis of COVID-19 MESHD and/or influenza ( flu HGNC) at point of care is critical for efficient patient management and treatment for either of these diseases. Clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 & FluA+B (Veritor SARS-CoV-2/ Flu HGNC) triplex assay was characterized. The performance for SARS-CoV-2 detection was determined using two hundred and ninety-eight (298) specimens from patients reporting COVID-19 MESHD symptoms within 7 days from symptom onset (DSO) in comparison with Lyra(R) SARS-CoV-2 RT-PCR Assay ( Lyra SARS-CoV-2 MESHD). The Veritor SARS-CoV-2/ Flu HGNC Assay met the FDA EUA acceptance criterion with 95% overall agreement for SARS-CoV-2 test when compared to Lyra SARS-CoV-2. The performance for Flu HGNC A and Flu HGNC B detection was determined using 75 influenza-positive and 40 influenza-negative retrospective specimens in comparison with the previously FDA cleared BD Veritor System for Rapid Detection of Flu HGNC A+B (Veritor Flu HGNC). The Veritor SARS-CoV-2/ Flu HGNC also demonstrated 100% agreement with the Veritor Flu HGNC.

    A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 MESHD hospitalized patients from those hospitalized with other respiratory viral infections MESHD

    Authors: Sarah C Vick; Marie Frutoso; Florian Mair; Andrew J Konecny; Evan Greene; Caitlin R Wold; Jennifer Logue; Jim Boonyaratanakornkit; Raphael Gottardo; Joshua T Schiffer; Helen Y Chu; Martin Prlic; Jennifer M. Lund

    doi:10.1101/2021.03.25.21254376 Date: 2021-03-26 Source: medRxiv

    SARS-CoV-2 infection MESHD has caused a lasting global pandemic costing millions of lives and untold additional costs. Understanding the immune response to SARS-CoV-2 has been one of the main challenges in the past year in order to decipher mechanisms of host responses and interpret disease pathogenesis. Comparatively little is known in regard to how the immune response against SARS-CoV-2 differs from other respiratory infections MESHD. In our study, we compare the peripheral blood immune signature from SARS-CoV-2 infected MESHD patients to patients hospitalized pre-pandemic with Influenza Virus or Respiratory Syncytial Virus MESHD (RSV). Our in-depth profiling indicates that the immune landscape in patients infected by SARS-CoV-2 is largely similar to patients hospitalized with Flu HGNC or RSV MESHD. Similarly, serum cytokine and chemokine expression patterns were largely overlapping. Unique to patients infected with SARS-CoV-2 who had the most critical clinical disease state were changes in the regulatory T cell (Treg) compartment. A Treg signature including increased frequency, activation status, and migration markers was correlated with the severity of COVID-19 MESHD disease. These findings are particularly relevant as Tregs are being discussed as a therapy to combat the severe inflammation MESHD seen in COVID-19 MESHD patients. Likewise, having defined the overlapping immune landscapes in SARS-CoV-2, existing knowledge of Flu HGNC and RSV infections MESHD could be leveraged to identify common treatment strategies.

    Clinical evaluation of the molecular-based BD SARS-CoV-2/ Flu HGNC for the BD MAX™ System

    Authors: Sonia Paradis; Elizabeth Lockamy; Charles K Cooper; Stephen Young

    doi:10.1101/2021.02.23.21251915 Date: 2021-02-25 Source: medRxiv

    Efficient and accurate assays for the differential diagnosis of COVID-19 MESHD and/or influenza ( flu HGNC) could facilitate optimal treatment for both diseases. Diagnostic performance related to SARS-CoV-2 and Flu HGNC A/B detection was characterized for the BD SARS-CoV-2/ Flu HGNC for BD MAX System (MAX SARS-CoV-2/ Flu HGNC) multiplex assay in comparison with BD BioGx SARS-CoV-2 Reagents for BD MAX System ( BioGx SARS-CoV-2 MESHD) and the Cepheid Xpert(R) Xpress Flu HGNC/RSV (Xpert Flu HGNC). Two hundred and thirty-five nasopharyngeal specimens were obtained from external vendors. MAX SARS-CoV-2/ Flu HGNC had positive percent agreement (PPA) and negative percent agreement (NPA) values for SARS-CoV-2 and Flu HGNC A/B that met FDA-EUA acceptance criteria of >95%.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.